Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA12 | O43570 | 7/20 | 0.40 |
| ▸ | CA9 | Q16790 | 7/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | RRM1 | P23921 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580120 | 0.86 | GNAI3 (0.47) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL19934130 | 0.86 | MEN1 (0.44) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL16757623 | 0.85 | MEN1 (0.43) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL16757624 | 0.85 | MEN1 (0.43) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL18543172 | 0.84 | CA2 (0.42) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL30859233 | 0.84 | GNAI3 (0.51) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL12196512 | 0.84 | GNAI3 (0.51) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL13790284 | 0.84 | DPP7 (0.54) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL8259792 | 0.84 | GNAI3 (0.51) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL24192956 | 0.82 | DPP7 (0.48) | TDP1MEN1KMT2AGAACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | LUMIPHORE, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | CLTB, CLTA, EPCAM | TDP1 3621/4885MEN1 2259/4885KMT2A 3740/4885 |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | CLTB, CLTA, EPCAM | TDP1 3621/4885MEN1 2259/4885KMT2A 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.